Ireland ready to be global leader in high-value biopharma services
A new BioPharma Business Services (BBS) strategy will be launched today for Ireland's biopharmaceutical and chemical sector.
The strategy aims to position Ireland as a hub for global services by leveraging the country's position as a leading manufacturing location and diversifying and strengthening the industry ecosystem in the country.
BioPharmaChem Ireland (BPCI), the Ibec group that represents the sector, launches the strategy at the Impact 2025 conference and awards taking place at the Killashee House Hotel in Naas.
Nearly 9,500 professionals, representing close to 20% of total BioPharmaChem employment in Ireland, work in BBS. BBS is one of the fastest growing industry segments, expected to grow by 10% by 2027.
"Our new strategy focuses on value stream enhancement, talent development, cutting-edge digital and AI infrastructure, and a vibrant ecosystem, to position Ireland as the global leader in innovative, high-value biopharma services," said Pfizer finance and global business services vice president Aoife Allen, who is the chair of BPCI's BBS steering committee.
More than 300 life science professionals are attending the conference in Naas. "It's an important time for the ecosystem to come together to understand the challenges and explore opportunities to support the development of the industry," said BioPharmaChem Ireland director Sinead Keogh.
"To ensure competitiveness, it is vital that Ireland prioritises investments in critical areas such as skills and talent, energy and infrastructure, public sector research and innovation, and regulatory simplicity. We welcome the new Government's commitment to a National Life Sciences Strategy and Action Plan on Competitiveness and Productivity. These priorities must remain at the forefront of policy agendas to secure the sector's long-term resilience."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Irish Independent
5 days ago
- Irish Independent
Wicklow and Wexford farmers invited to see solar energy in action at on-farm event
Part of a series of 'Solar In Action' events showcasing rooftop solar installations by IFA and Bord Gáis Energy that have delivered savings on working farms nationwide, the Wexford leg of the roadshow will take place on the farm of Paul Kehoe in Glasscarrig, Ballygarrett, on July 14 at 8 pm. Farmers attending will hear first-hand from those who have already installed rooftop solar, learning about their experience, costs, benefits, and practical insights into how it's working on their farms. Speakers from IFA and Bord Gáis Energy will also present details on the application process, TAMS, and the technology used by IFA and Bord Gáis Energy. The event series also highlights the support available to farmers through the TAMS 3 Solar Capital Investment Scheme, which offers grant aid of up to 60pc for eligible rooftop solar installations. 'Farmers are stepping up to the energy challenge and 'Solar In Action' shows the real, practical steps farms can take to cut costs and carbon,' IFA president Francie Gorman said. 'These are working farms, already producing their clean energy with IFA-Bord Gáis Energy rooftop systems – and the TAMS grant makes it even more accessible'. 'Rooftop solar power solutions are helping farmers reduce energy costs – saving up to €200,000 across the lifetime of a typical installation – while supporting the long-term sustainability of their farms,' Bord Gáis Energy's John Cussen added. 'The 'Solar In Action' roadshow gives farmers the chance to see the technology in action, hear from others already seeing the benefits, and speak with experts about how solar could work for their own farm. 'With strong demand across the agriculture sector, solar is the smart, future-focused choice for farms of all types and sizes.' The free event is open to all farmers. Register via
The Journal
03-06-2025
- The Journal
Applications open for the free college courses on offer for the next academic year
APPLICATIONS ARE NOW open for Springboard, an initiative that offers free and heavily subsidised college courses. The courses on offer for this year were announced last week . They are mainly available in areas aligning with national economic priorities such as infrastructure planning, sustainable building, renewable energy, digital skills, cyber security, and artificial intelligence. You can view here the full list of courses made available. The courses are provided 'at certificate, degree, and masters level leading to qualifications in areas where there are employment opportunities in the economy'. Minister for Further and Higher Education James Lawless said that the initiative is 'one of the most impactful' investments made by the government in further education. The courses on offer are designed to respond to evolving skills demands. 'It offers thousands of learners the chance to upskill or reskill in areas where Ireland needs talent from artificial intelligence to infrastructure planning to cybersecurity,' he said. Lawless added that Springboard is meant to make upskilling more accessible and achievable for everyone. Advertisement It will deliver 7,719 places across 249 courses for the 2025/26 academic year. All courses will commence between 1 July and 31 October 2025. Courses are flexible and accessible, with 96% delivered online or in blended format, designed to support working professionals, jobseekers, and those returning to further education alike, the department said. Some of the universities offering courses that are covered include Trinity College Dublin, Dublin City University, University College Cork, University of Galway, University of Limerick, and University College Dublin. A large number of places are also available in technological universities and institutes, with a large volume available for applications in ATU campuses across Ireland. You can check your eligibility for the initiative here . You must have a valid PPS number and be living full-time in the Republic of Ireland. 'Applicants currently unemployed, or seeking to return to the workforce after a career break to care for loved ones, qualify for a free place on a higher education course,' a statement said. If you are in employment, 90% of the total fees are covered by Springboard, with the remaining 10% covered either by the applicant or their employer. Readers like you are keeping these stories free for everyone... A mix of advertising and supporting contributions helps keep paywalls away from valuable information like this article. Over 5,000 readers like you have already stepped up and support us with a monthly payment or a once-off donation. Learn More Support The Journal
RTÉ News
03-06-2025
- RTÉ News
'Hope on horizon' as new drugs tested for Alzheimer's treatment
Dementia experts have said that "hope is on the horizon" after a new review shows a rise in the number of potential drugs that could treat or prevent Alzheimer's disease. Some 138 new treatments are being assessed for the treatment and prevention of Alzheimer's. A third of drugs currently being trialled are "repurposed" medications that are already being used to tackle other diseases, including diabetes, multiple sclerosis and cholesterol, according to the new review. One such trial is assessing whether semaglutide, the main ingredient for the weight loss and diabetes drug Ozempic and weight loss drug Wegovy, can slow the progression of dementia. And four late-stage trials are looking at preventing disease. Experts said that drugs targeting amyloid protein build up in the brain, such as lecanemab and donanemab, are "only one part of the overall strategy" as they expressed excitement over the variety of new drugs, which are being tested among patients. The new review of Alzheimer's disease in clinical trials in 2025 found 182 clinical trials assessing the impact of 138 drugs. The number of trials represents an 11% increase on the previous year, according to the review, which was led by an expert from the University of Nevada in the US and has been published in the journal Alzheimer's and Dementia: Translational Research and Clinical Interventions. Commenting on the paper, Dr Sheona Scales, director of research at Alzheimer's Research UK, said: "This year has really given us real cause for optimism." She said that as well as more drugs coming through the pipeline, the treatment targets are "more diverse" and "looking at all stages of the disease". She added: "What this paper is showing us is that the pipeline of drug development is growing, it's diversifying and accelerating." "This latest report shows us that there is hope on the horizon for people with Alzheimer's, building on lecanemab and donanemab." Dr Emma Mead, chief scientific officer of the Oxford Drug Discovery Institute, added: "Today we are at a tipping point in dementia research as we understand more and more about the diseases that drive dementia. "This gives us opportunities to slow and ultimately stop this devastating condition and today's announcement demonstrates that researchers are able to translate these understandings towards potential new treatments." James Rowe, professor of cognitive neurology at the University of Cambridge and consultant neurologist, said: "What strikes me is not just the number of new drugs, which is increasing year on year, but their range of targets (and) the range in which they work, giving us multiple shots on goal." On the drugs which are being investigated for the prevention of disease, Prof Rowe said: "One of the most exciting things of this report is the number of large-scale late-stage trials on prevention. "And the aspiration to prevent, not just treat, is starting to be seen in the figures we see in these charts today." He added: "One way this can work is you take a treatment that you show to be working in people with symptoms with the illness, and then you simply bring it forward by some years. "The ones that are in trial at the moment are really... bringing forward an effective treatment to earlier stage." For instance, people with a genetic risk of Alzheimer's could receive some drugs earlier to see if they protect against the disease. On the repurposing of current drugs, Dr Mead said that it can usually take ten to 15 years for new drugs to be tested and approved for use. "Being able to repurpose drugs licensed for other health conditions could help to accelerate progress and help to open up other avenues to prevent or treat dementia causing diseases," she said. "A really promising example of this is the drug semaglutide, which is currently being trialled in people with mild cognitive impairment." Meanwhile, academics said lecanemab and donanemab, which can be used for treating mild cognitive impairment in Alzheimer's patients, are an "important first step" in the battle against the disease. The treatments were initially approved for UK use by regulators but then deemed not cost-effective for NHS use. The National Institute for Health and Care Excellence (NICE) is taking more evidence on donanemab and lecanemab and is expected to announce its decision in the summer. Dr Scales added: "Lecanemab and donanemab have represented a huge leap forward in our understanding and ability to be able to treat Alzheimer's disease. "What they've done is they've proved that we're able to modify the course of Alzheimer's disease, and what that has done is opened up the door to future treatments that we hope are more effective, easier to deliver and able to deliver for our patients." She said studies are showing "even more complexities" around Alzheimer's and that in the future, people may be treated with a combination of drugs, depending on when they are diagnosed and the type of dementia they have.
